Study of BL-ARC002 for advanced gastrointestinal and other solid tumors
Part of Cancer, Digestive system clinical trials.
This trial tests an investigational drug called BL-ARC002 for people with advanced or metastatic cancers of the esophagus, stomach, colon, rectum, or other solid tumors. The goal is to see if it is safe and effective in treating these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with locally advanced or metastatic esophageal, gastric, colorectal, or other solid tumor cancer.
- You can provide a tumor tissue sample from within the last 2 years or agree to a fresh biopsy.
- You have at least one measurable tumor site that can be tracked by imaging.
- Your overall health status is good: able to care for yourself and up and about more than 50% of waking hours (ECOG 0 or 1).
- You have not had certain heart conditions, and your heart's pumping ability is at least 50%.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new cancer drug called BL-ARC002 in patients whose advanced or spread cancers (solid tumors) have not responded to standard treatments. The drug is an antibody designed to help the immune system fight cancer.
This trial tests a new radioactive drug (Lutetium-177 BL-ARC001) for people with advanced solid tumors, including stomach, bowel, and other cancers. It aims to see if the treatment is safe and how well it works.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This trial tests a new drug, BL-M24D1, in people with advanced or metastatic digestive tract cancers or other solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
This trial tests a new drug called BL-M08D for people with advanced digestive tract tumors or other solid tumors that have spread. It aims to see if the drug can shrink tumors and improve survival, while monitoring safety.
This trial tests a new drug called BL-B16D1 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if this drug is safe and how well it works.
Hear when a new Gastrointestinal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.